Milestone Scientific (MLSS) Competitors

Profound Medical (NASDAQ:PROF) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Which has more volatility & risk, PROF or MLSS?

Profound Medical has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Does the media favor PROF or MLSS?

In the previous week, Milestone Scientific had 10 more articles in the media than Profound Medical. MarketBeat recorded 15 mentions for Milestone Scientific and 5 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.60 beat Milestone Scientific's score of 0.12 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Milestone Scientific	1 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer PROF or MLSS?

Profound Medical received 39 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 72.73% of users gave Profound Medical an outperform vote while only 1.39% of users gave Milestone Scientific an outperform vote.

Company	Underperform	Outperform
Profound Medical	Outperform Votes 40 72.73%	Underperform Votes 15 27.27%
Milestone Scientific	Outperform Votes 1 1.39%	Underperform Votes 71 98.61%

Which has higher valuation & earnings, PROF or MLSS?

Milestone Scientific has higher revenue and earnings than Profound Medical. Milestone Scientific is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$7.20M	27.43	-$28.57M	-$1.34	-5.98
Milestone Scientific	$9.83M	5.11	-$6.93M	-$0.07	-9.28

Do analysts recommend PROF or MLSS?

Profound Medical presently has a consensus target price of $13.75, suggesting a potential upside of 71.66%. Milestone Scientific has a consensus target price of $1.25, suggesting a potential upside of 92.31%. Given Milestone Scientific's higher probable upside, analysts plainly believe Milestone Scientific is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of PROF or MLSS?

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 24.8% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is PROF or MLSS more profitable?

Milestone Scientific has a net margin of -52.01% compared to Profound Medical's net margin of -349.41%. Milestone Scientific's return on equity of -59.12% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-349.41%	-85.22%	-64.87%
Milestone Scientific	-52.01%	-59.12%	-39.88%

Summary

Milestone Scientific beats Profound Medical on 10 of the 19 factors compared between the two stocks.